As such, the observed changes in CET may be attributed to BAK toxicity, to the direct effects of active ingredients in antiglaucoma eyedrops, or less likely to the intrinsic pathologic mechanism of glaucoma. This evidence concerns the gene BAK1 and glaucoma.